Prothena Corporation plc

Publicly traded biopharmaceutical companies have faced a rough year for fundraising in 2025 with the amount of money raised across all financing types down significantly from 2024 levels during the

The Parkinson’s field is littered with clinical failures and another candidate, UCB’s minzasolmin, is the latest to fall in the quest for a disease modifying treatment. The Belgium-based group has i

S.Biomedics’ stem cell therapy for Parkinson’s disease has shown positive results in an assessment of one-year data from the three patients (first low-dose cohort) in a Phase I/IIa clinical trial, rai

Biopharma companies work hard to stack their pipelines with promising candidates. But which candidates are the most promising? A recent report from Evaluate finds that the top three pipeline assets